• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国阿片类药物过量死亡与治疗能力之间的差距:一项地理空间和描述性分析。

Disparities Between US Opioid Overdose Deaths and Treatment Capacity: A Geospatial and Descriptive Analysis.

机构信息

University of Texas Health Science Center at Houston, Houston, TX.

出版信息

J Addict Med. 2019 Nov/Dec;13(6):476-482. doi: 10.1097/ADM.0000000000000523.

DOI:10.1097/ADM.0000000000000523
PMID:30844879
Abstract

INTRODUCTION

With opioid-related deaths reaching epidemic levels, gaining a better understanding of access to treatment for opioid use disorder (OUD) is critical. Most studies have focused on 1 side of the equation-either provider capacity or patients' need for care, as measured by overdose deaths. This study examines the overlay between treatment program availability and opioid mortality, comparing accessibility by region.

METHODS

Geospatial and statistical analyses were used to model OUD treatment programs relative to population density and opioid overdose death incidence at the state and county level. We computed a ratio between program capacity and mortality called the programs-per-death (PPD) ratio.

RESULTS

There were 40 274 opioid deaths in 2016 and 12 572 treatment programs across the contiguous 48 states, yielding a ratio of 1 program for every 3.2 deaths. Texas had the lowest number of treatment programs per 100 000 persons (1.4) and Maine the highest (13.2). West Virginia ranked highest in opioid deaths (39.09 per 100 000). Ohio, the District of Columbia, and West Virginia had the greatest mismatch between providers and deaths, with an average of 1 program for every 8.5 deaths. Over 32% of US counties had no treatment programs and among those with >10 deaths, nearly 2.5% had no programs. Over 19% of all counties had a ratio ≤1 provider facility per 10 deaths.

CONCLUSION

Assessing the overlay between treatment capacity and need demonstrated that regional imbalances exist. These data can aid in strategic planning to correct the mismatch and potentially reduce mortality in the most challenged geographic regions.

摘要

简介

随着阿片类药物相关死亡人数达到流行水平,深入了解治疗阿片类药物使用障碍(OUD)的途径至关重要。大多数研究都集中在等式的一方——提供者能力或患者对护理的需求,这是通过过量死亡来衡量的。本研究通过比较区域间的治疗方案可及性,检查治疗方案的可用性与阿片类药物死亡率之间的重叠。

方法

使用地理空间和统计分析来模拟与人口密度和州和县一级阿片类药物过量死亡发生率相关的 OUD 治疗方案。我们计算了一个称为每死亡人数治疗方案(PPD)比率的方案能力与死亡率之间的比率。

结果

2016 年有 40274 例阿片类药物死亡和 12572 个治疗方案分布在 48 个州,每 3.2 例死亡就有 1 个治疗方案。得克萨斯州每 10 万人拥有的治疗方案数量最少(1.4),缅因州最高(13.2)。西弗吉尼亚州的阿片类药物死亡率最高(39.09 例/10 万人)。俄亥俄州、哥伦比亚特区和西弗吉尼亚州的提供者和死亡人数之间的不匹配程度最大,平均每 8.5 例死亡就有 1 个治疗方案。超过 32%的美国县没有治疗方案,在有超过 10 例死亡的县中,近 2.5%没有治疗方案。超过 19%的县每 10 例死亡的治疗方案数≤1。

结论

评估治疗能力与需求之间的重叠表明存在区域失衡。这些数据可以帮助进行战略规划,以纠正最具挑战性的地理区域的不匹配,并有可能降低死亡率。

相似文献

1
Disparities Between US Opioid Overdose Deaths and Treatment Capacity: A Geospatial and Descriptive Analysis.美国阿片类药物过量死亡与治疗能力之间的差距:一项地理空间和描述性分析。
J Addict Med. 2019 Nov/Dec;13(6):476-482. doi: 10.1097/ADM.0000000000000523.
2
Characteristics of US Counties With High Opioid Overdose Mortality and Low Capacity to Deliver Medications for Opioid Use Disorder.具有高阿片类药物过量死亡率和提供阿片类药物使用障碍治疗能力低的美国县的特征。
JAMA Netw Open. 2019 Jun 5;2(6):e196373. doi: 10.1001/jamanetworkopen.2019.6373.
3
Comparison between buprenorphine provider availability and opioid deaths among US counties.美国各县的丁丙诺啡提供情况与阿片类药物死亡人数比较。
J Subst Abuse Treat. 2018 Oct;93:19-25. doi: 10.1016/j.jsat.2018.07.008. Epub 2018 Jul 20.
4
County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.与阿片类药物过量死亡率和阿片类药物治疗设施可及性不匹配相关的县级因素。
PLoS One. 2024 Apr 5;19(4):e0301863. doi: 10.1371/journal.pone.0301863. eCollection 2024.
5
County-level access to opioid use disorder medications in medicare Part D (2010-2015).医疗保险部分 D 中县级获得阿片类使用障碍药物的情况(2010-2015 年)。
Health Serv Res. 2019 Apr;54(2):390-398. doi: 10.1111/1475-6773.13113. Epub 2019 Jan 21.
6
Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.受控物质处方模式 - 处方行为监测系统,八个州,2013 年。
MMWR Surveill Summ. 2015 Oct 16;64(9):1-14. doi: 10.15585/mmwr.ss6409a1.
7
Identifying counties at risk of high overdose mortality burden during the emerging fentanyl epidemic in the USA: a predictive statistical modelling study.识别美国芬太尼流行期间高过量死亡率负担风险的县:预测统计建模研究。
Lancet Public Health. 2021 Oct;6(10):e720-e728. doi: 10.1016/S2468-2667(21)00080-3. Epub 2021 Jun 10.
8
Preliminary results of the evaluation of the California Hub and Spoke Program.加利福尼亚轴心辐射计划评估的初步结果。
J Subst Abuse Treat. 2020 Jan;108:26-32. doi: 10.1016/j.jsat.2019.07.014. Epub 2019 Aug 1.
9
Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.美国各州阿片类药物使用障碍药物的使用情况:与治疗可用性和过量死亡率的关系。
J Addict Med. 2022;16(1):114-117. doi: 10.1097/ADM.0000000000000820.
10
U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018.2016 年和 2018 年美国具有开具丁丙诺啡用于治疗阿片类药物使用障碍处方豁免资质的提供者供应趋势。
Drug Alcohol Depend. 2019 Nov 1;204:107527. doi: 10.1016/j.drugalcdep.2019.06.029. Epub 2019 Aug 30.

引用本文的文献

1
Filling the Treatment Gap: Geographic Expansion of Buprenorphine Providers Across the U.S.填补治疗缺口:丁丙诺啡提供者在美国的地域扩张
AJPM Focus. 2024 Oct 16;4(1):100284. doi: 10.1016/j.focus.2024.100284. eCollection 2025 Feb.
2
Trends in Drug and Polysubstance-Related Deaths in the State of Texas: County Comparisons.德克萨斯州与毒品和多种物质相关的死亡趋势:县际比较
Cureus. 2025 Feb 17;17(2):e79175. doi: 10.7759/cureus.79175. eCollection 2025 Feb.
3
RREACT: A mobile multidisciplinary response to overdose.RREACT:对药物过量的多学科移动应对措施。
J Community Saf Well Being. 2024;9(1):19-26. doi: 10.35502/jcswb.360. Epub 2024 Mar 14.
4
Lessons for future pandemics: Temporal evolution and rural-urban variations in the impacts of the COVID-19 on opioid use treatment.未来大流行的教训:COVID-19 对阿片类药物使用治疗的影响的时间演变和城乡差异。
PLoS One. 2024 Sep 13;19(9):e0310386. doi: 10.1371/journal.pone.0310386. eCollection 2024.
5
Disparities in Access to Highly Rated Skilled Nursing Facilities among Medicare Beneficiaries with Opioid Use Disorder.患有阿片类药物使用障碍的医疗保险受益人群在获得高评级熟练护理设施方面的差异。
J Am Med Dir Assoc. 2024 Oct;25(10):105190. doi: 10.1016/j.jamda.2024.105190. Epub 2024 Aug 5.
6
County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.与阿片类药物过量死亡率和阿片类药物治疗设施可及性不匹配相关的县级因素。
PLoS One. 2024 Apr 5;19(4):e0301863. doi: 10.1371/journal.pone.0301863. eCollection 2024.
7
Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review.田纳西州的美沙酮治疗缺口以及药物治疗单位如何填补这一缺口:一项综述
Pharmacy (Basel). 2023 Aug 22;11(5):131. doi: 10.3390/pharmacy11050131.
8
Availability of Medication for Opioid Use Disorder Among Accountable Care Organizations: Evidence From a National Survey.《问责制医疗组织中阿片类药物使用障碍药物的供应情况:来自全国性调查的证据》。
Psychiatr Serv. 2024 Feb 1;75(2):182-185. doi: 10.1176/appi.ps.20230087. Epub 2023 Aug 24.
9
A qualitative exploration of barriers and facilitators to drug treatment services among people who inject drugs in west Virginia.西弗吉尼亚州注射吸毒者获得药物治疗服务的障碍和促进因素的定性探索。
Harm Reduct J. 2023 Jun 1;20(1):69. doi: 10.1186/s12954-023-00795-w.
10
History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder.丁丙诺啡药物用于治疗阿片类物质使用障碍的发现、研发及美国食品药品监督管理局批准历程。
Drug Alcohol Depend Rep. 2023 Jan 10;6:100133. doi: 10.1016/j.dadr.2023.100133. eCollection 2023 Mar.